Decoy Therapeutics Appoints MIT's Brad Pentelute as Scientific Advisory Board Chair to Advance Antiviral Innovations

Decoy Therapeutics Enhances Scientific Leadership with Appointment of Brad Pentelute

Decoy Therapeutics Inc., a company at the forefront of antiviral innovation, has taken a significant step towards strengthening its scientific leadership. On May 26, 2026, the company announced the appointment of Dr. Brad L. Pentelute, a respected Professor of Chemistry at the Massachusetts Institute of Technology (MIT), as the new Chair of its Scientific Advisory Board (SAB). This strategic move aligns with Decoy's mission to revolutionize antiviral treatments through its cutting-edge Designable Multi-Antivirals (D-MAVs™) platform.

As an original co-founder of Decoy, Dr. Pentelute has played a crucial role in the company’s journey since its inception. His background in peptide synthesis and protein engineering has earned him recognition as a leading expert in the field. In his new role, Dr. Pentelute will guide the scientific direction of the IMP3ACT™ platform, which underpins the development of Decoy's expanding antiviral pipeline.

Understanding D-MAVs™: A New Frontier in Antiviral Development

Decoy Therapeutics is pioneering a new class of antiviral treatments, D-MAVs™, designed to target common mechanisms shared across various viruses. This approach enables the potential for a single drug to combat multiple viral threats, moving away from the traditional model of developing individual drugs for specific viruses. The IMP3ACT™ platform utilizes AI-accelerated design and rapid synthesis techniques, paving the way for faster and more efficient drug development processes.

Rick Pierce, CEO of Decoy Therapeutics, expressed enthusiasm regarding Dr. Pentelute's appointment, stating, "Brad has been part of Decoy's science from the start. His insights have shaped Decoy from our earliest days, and his leadership will help us navigate the next phase of our journey." Pierce also acknowledged the contributions of Shahin Gharakhanian, previous Chair of the SAB, highlighting the foundational role he played during the initial phases of the company’s development.

Dr. Pentelute shared his excitement about his expanded role, emphasizing that traditional antiviral strategies have been limited by a one-virus, one-drug framework. He sees the D-MAVs™ approach as a transformative shift, providing a comprehensive solution by addressing multiple viral challenges simultaneously. "The combination of peptide chemistry, rapid synthesis, and AI-enabled design opens up real possibilities," he noted, reiterating the importance of innovation in antiviral treatments.

Strengthening the Future of Antiviral Research

Dr. Pentelute's appointment comes at a time when the global landscape is increasingly marked by emerging viral threats. Decoy's focus on respiratory viruses, which have been a significant source of health and societal challenges, makes the work of the company particularly relevant. The advancements in antiviral technologies could profoundly impact the way we approach viral infections, potentially improving patient outcomes on a global scale.

In summary, Decoy Therapeutics is poised to make substantial strides in antiviral research with the leadership of Dr. Brad Pentelute. His expertise and vision align perfectly with Decoy’s goals, positioning the company to play a leading role in the future of medicine. As the landscape evolves, the importance of adaptable and flexible antiviral solutions will continue to grow, and Decoy's innovative approach may very well redefine the industry standards.

For further information about Decoy Therapeutics and its initiatives, you can visit their official website at decoytx.com.